These molecular groups also form the basis for personalized treatment of endometrial carcinomas based on the molecular classification, for example, de‐escalation of treatment in POLEmut tumors, immune checkpoint inhibitors in MMRd and POLEmut neoplasms, and chemotherapy in p53abn, while in NSMP tumors, which are hormone receptor positive, hormonal therapy may be an option.5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16. Here, NR4A1 is linked to neoplasm.